Biocompatible de novo indolylchalcones as platelet aggregation inhibition and diabetic wound healing agents

RSC Medicinal Chemistry 2026 Open access

Read full text
Authors: Sumit Kumar, Radhika Chaurasia, Gaurav Kumar, Arun K. Sharma, Ijaz Ahmed, Alam Nur-E-Kamal, Monalisa Mukherjee, Brajendra K. Singh, Virinder S. Parmar
DOI: 10.1039/d5md00984g
Cited by: 3
References: 65

Abstract

-acylated derivatives (20-27) are synthesised to explore their potential as multifunctional therapeutic agents. Compounds 24 and 25 demonstrate NOS activation (350-450% increase) and anti-platelet aggregation (40-45% inhibition), improving microvascular circulation and reducing thrombotic risk. They exhibited minimal cytotoxicity in NIH3T3 cells and negligible hemolytic activity. Notably, in diabetic wound models, compounds 24 and 25 accelerated wound healing by improving eNOS/NO levels, promoting angiogenesis, enhancing tissue regeneration, and modulating inflammatory cytokines, including marked reduction in IL-1β and TNF-α levels. Their dual functionality, vascular protection and regenerative potential positions indolylchalcones as promising candidates for future development in cardiovascular and wound-healing therapies.

Fields of Study & Subjects

Synthesis of Indole Derivatives Neutrophil Myeloperoxidase and Oxidative Mechanisms Wound Healing and Treatments

Publication details

Journal / source
RSC Medicinal Chemistry
Publisher
Royal Society of Chemistry (RSC)
Volume
17
Issue
4
Pages
1916–1937
Publication date
1 January 2026
Language
EN